Background: The combination of durvalumab and tremelimumab results in clinical benefit, with a tolerable safety profile in patients with solid tumors. Objective: To evaluate the efficacy and safety of durvalumab in combination with tremelimumab compared with either drug alone. Methods: The online databa...
The addition of tremelimumab to first-line durvalumab significantly improved OS compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer. The combination also exhibited a favorable safety profile, res...
Serious TRAEs were observed in 24.6% of patients in the tremelimumab group, 17.6% of patients treated with 300 mg of intravenous tremelimumab for 1 cycle (T300) plus 1500 mg of durvalumab, 10.9% of patients in the durvalumab arm, and 14.6% of patients treated with 75 mg of i...
52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC) Author links open overlay panelA. Vogel 1, S. Boeck 2, O. ...
Durvalumab, a human IgG1κ anti–PD-L1 monoclonal antibody, and tremelimumab, a fully humanized IgG2 anti–CTLA-4 monoclonal antibody, activate and enhance T cell function by means of distinct and complementary mechanisms.11,12 Although the combination did not improve survival compared with chemothe...
Here, we present results of a multi-center, randomized, phase II trial (PA.7; NCT02879318) that aimed to assess the safety and efficacy of combination chemotherapy/ICI in mPDAC by comparing gemcitabine, nab-paclitaxel plus durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor) versus...
What is the most important information I should know about IMFINZI®(durvalumab) and IMJUDO®(tremelimumab-actl)? IMFINZI and IMJUDO are medicines that may treat certain cancers by working with your immune system. IMFINZI and IMJUDO can cause... ...
4073 Background: Durvalumab and tremelimumab, investigational monoclonal antibodies against PD-L1 and CTLA-4 immune checkpoints, respectively, have shown efficacy in monotherapy and offer promise in combination for patients (pts) with HCC. This is a phase I/II, open-label, randomized study of dur...
A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour muta... e15581 Background: The randomized phase II CCTG CO.26 clinical trial investigated the use of combined durvalumab and tremelimumab vs. best ...
Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant. Given the success of immunotherapy in the advanced setting, it is imperative to study this in the pre-transplant setting, to improve the outcomes cited ... D Sohal,KF Abouelezz,K Moreland,... -...